Cobra Venom Factor

Uniform pool of Cobra Venom Factor (CVF), a non-toxic complement activating reagent.


Product Specifications

Citations26
Description

Uniform pool of Cobra Venom Factor (CVF), a non-toxic complement activating reagent.

Storage

Store at -70°C or below. Minimize freeze/thaw cycles.

Form

Frozen liquid (Phosphate Buffered Saline, pH 7.2 ± 0.2)

Concentration

1.0-1.2 mg/mL

Applications

See citations and technical data sheet for application info.

Ordering Information

For Research Use Only. Not for use in diagnostic procedures.
Catalog NumberA600
Catalog Number (CE)N/A
Size1.0 mg
Price (USD)$400.00
Price (EURO)355,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

Uniform pool of Cobra Venom Factor (CVF), a non-toxic complement activating reagent.

Size1.0 mg
Storage

Store at -70°C or below. Minimize freeze/thaw cycles.

Form

Frozen liquid (Phosphate Buffered Saline, pH 7.2 ± 0.2)

Concentration1.0-1.2 mg/mL
ApplicationsSee citations and technical data sheet for application info.
Purity≥ 95% by SDS page
SourceNaja naja kaouthia (cobra)
Activity8 units/mL to 20 units/mL for full complement conversion.
Molecular WeightN/A
Background

Cobra Venom Factor (CVF), sometimes referred to as C3b(Cobra), is the non-toxic, complement activating component of cobra venom. Like naturally occurring C3b, CVF forms a complex with complement components Factor B and Factor D. This CVFBbD convertase is capable of activating C3 in a wide variety of species via the alternative complement pathway. Unlike the naturally occurring convertase (C3bBbD), the C3b(Cobra)BbD convertase is Factor H resistant and is therefore not inactivated by Factor I or CR1. Given appropriate incubation time, CVF will convert nearly 100% of the C3 to C3 end products. Unlike CVF purified from the Naja naja haje species, CVF from Naja naja kaouthia activates the terminal pathway directly by forming a C5 convertase. This depletes C5 in a manner analogous to that described above for C3. Levels of iC3b, C3a, SC5b-9, C5a and the Factor B cleavage product Bb are all extremely high in CVF treated sera.

Citations

TitleYearApplicationsSample SpeciesSampleSample Details

Soluble MAC is primarily released from MAC-resistant bacteria that potently convert complement component C5.

2022Complement Depletion AssayHuman

Serum

N/A

A Conformational Change of Complement C5 Is Required for Thrombin-Mediated Cleavage, Revealed by a Novel Ex Vivo Human Whole Blood Model Preserving Full Thrombin Activity.

2021WBHuman

Purified protein

N/A

Graphene Oxide Nanosheets for Localized Hyperthermia-Physicochemical Characterization, Biocompatibility, and Induction of Tumor Cell Death.

2020Complement Activation AssayHuman

Plasma

N/A

Discovery of monoclonal antibodies cross-reactive to novel subserotypes of K. pneumoniae O3

2017Complement Depletion AssayHuman

Serum

N/A

Endotoxin neutralization by an O-antigen specific monoclonal antibody: A potential novel therapeutic approach against Klebsiella pneumoniae ST258

2017Complement Depletion AssayMouse

Protein Injection

N/A

Complement Depletion Improves Human Red Blood Cell Reconstitution in Immunodeficient Mice

2017Complement Depletion AssayMouse

Serum

N/A

Nanoparticles size-dependently initiate self-limiting NETosis-driven inflammation

2016Complement Activation AssayHuman

Serum

N/A

Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft

2016Complement Depletion AssayBaboon

Protein Injection

N/A

Molecular response of chorioretinal endothelial cells to complement injury: implications for macular degeneration

2016Complement Depletion AssayHuman

Serum

N/A

Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G

2016Complement Depletion AssayRat

Protein Injection

N/A

Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies

2016Complement Depletion AssayRat

Protein Injection

N/A

Efficiency of conditionally attenuated Salmonella enterica serovar Typhimurium in bacterium-mediated tumor therapy

2015Complement Depletion AssayMouse

Protein Injection

N/A

Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques

2015Complement Depletion AssayRat

Protein Injection

N/A

Yersinia pseudotuberculosis uses Ail and YadA to circumvent neutrophils by directing Yop translocation during lung infection

2014Complement Depletion AssayMouse

Protein Injection

N/A

C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independent in vivo

2014Complement Depletion AssayMouse

Protein Injection

N/A

No expression of porcine endogenous retrovirus after pig to monkey xenotransplantation

2014Complement Depletion AssayPorcine

Protein Injection

N/A

SIGN-R1, a C-type lectin, enhances apoptotic cell clearance through the complement deposition pathway by interacting with C1q in the spleen

2013Complement Depletion AssayMouse

Protein Injection

N/A

Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1β release

2013Complement Depletion AssayMouse

Protein Injection

N/A

Intravital immunofluorescence for visualizing the microcirculatory and immune microenvironments in the mouse ear dermis

2013IFMouse

Ear dermis Tissue

N/A

Up to 9-day survival and control of thrombocytopenia following alpha1,3-galactosyl transferase knockout swine liver xenotransplantation in baboons

2012Complement Depletion AssayBaboon

Protein Injection

N/A

Zwitterionic chitosan derivatives for pH-sensitive stealth coating

2010Complement Activation AssayHuman

Plasma

N/A

Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles

2009Complement Activation AssayHuman

Plasma

Gold Nanoparticles incubated

Natural antibody to conserved targets of Haemophilus influenzae limits colonization of the murine nasopharynx

2009Complement Depletion AssayMouse

Protein Injection

N/A

Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production

2009Complement Depletion AssayMouse

Protein Injection

N/A

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV

2008Complement Depletion AssayMouse

Protein Injection

N/A

The role of innate immune responses in the outcome of interspecies competition for colonization of mucosal surfaces

2005Complement Depletion AssayMouse

Protein Injection

N/A